Using a special PET scan to measure oxygen levels in lung cancer
A Feasibility Study of Hypoxia Imaging in Patients With Lung Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)
This study is testing a special PET scan to see if it can measure low oxygen levels in lung cancer patients before they start radiation treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT02701699 on ClinicalTrials.gov |
What this trial studies
This study aims to assess low oxygen levels, known as hypoxia, in lung cancer patients using a positron emission tomography (PET) scan with a radiotracer called Fluoroazomycin Arabinoside (FAZA). The study will involve patients with stage II or III lung cancer who are scheduled to receive radiotherapy. Participants will undergo a FAZA PET scan prior to their first radiotherapy treatment to determine if this method can provide valuable insights into tumor hypoxia and its impact on treatment response.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with stage II or III lung cancer who are eligible for radiotherapy.
Not a fit: Patients with previous radiotherapy to the treatment area or other active malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the understanding of tumor hypoxia in lung cancer, potentially leading to improved treatment strategies.
How similar studies have performed: Previous studies using FAZA PET imaging in various cancers have shown promise, suggesting this approach may be beneficial in lung cancer as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Patients with stage II or III lung cancer (both NSCLC and SCLC) qualifying for radiotherapy to the primary tumor, with or without treatment of mediastinal or hilar lymph nodes 3. Intention to treat using radiotherapy according to the current treatment policies of the PMH Lung Group 4. Concurrent systemic therapy allowed 5. A negative serum pregnancy test within the two week interval immediately prior to PET-CT imaging, in women of child-bearing age 6. Ability to provide written informed consent to participate in the study Exclusion Criteria: 1. Previous radiotherapy to intended treatment volumes. 2. Previous systemic therapy 3. Active malignancy other than lung cancer 4. Unable to remain supine for more than 60 minutes 5. Pregnancy 6. Age less than 18 years old 7. Failure to provide written informed consent
Where this trial is running
Toronto, Ontario
- University Health Network, Princess Margaret Cancer Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Alex Sun, MD — The Princess Margaret Cancer Foundation
- Study coordinator: Alex Sun, MD
- Email: Alex.Sun@rmp.uhn.on.ca
- Phone: 416 946 4501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.